Ciclesonide Sought After in the U.S. Nasal Corticosteroid Market

Ciclesonide Sought After in the U.S. Nasal Corticosteroid Market

CiclesonideCiclesonide is a corticosteroid nasal spray, which is also known as the brand name Omnaris. With the patent for Omnaris due to expire on October 24, 2017, development for a generic product is sure to be underway. Ciclesonide works by preventing the release of substances in the body that cause inflammation, making this medication an excellent choice for patients with seasonal and year-round allergies. Adults and children age 12 and older will find relief using Ciclesonide to combat their frustrating nasal allergy symptoms, such as sneezing, congestion and a runny nose. The typical dose of Ciclesonide is two sprays, once a day, in each nostril. Side effects are minor, and may include nosebleeds, headaches or a sore throat.

Studies of Ciclesonide have proven to be indicative of success. One study, which involved 707 adult and adolescent patients who were at least 13 years of age, demonstrated efficacy across the board. This study was randomized in a double-blind manner, and patients received Ciclesonide HFA nasal aerosol 80 mcg or 160 mcg, or a placebo once daily for up to two weeks.  The patients in this study reported both in the morning and evening about their symptoms. Symptoms assessed were nasal congestion, itching, sneezing, runny nose and ocular symptoms like itching, tearing and redness of the eyes. Both active treatments of Ciclesonide 80 mcg and 160 mcg showed significantly clinical differences, statically, when compared to the patients who were administered the placebo. In addition, the safety and tolerability of Ciclesonide was established for all participants.

The U.S. market for nasal corticosteroids is estimated at approximately 2 billion dollars, and allergic rhinitis is the most common allergic disease in the United States. Allergic rhinitis and is believed to affect approximately 20 percent of all adults and 40 percent of children. An estimated 16.7 million physician office visits each year in the U.S. are attributed to allergic rhinitis, and continued research and development of treatments to combat this devitalizing condition are needed.

LGM Pharma provides the Ciclesonide CAS# 141845-82-1 API for research and development purposes, and offers clients continued support.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service